Table 3 Summative results of the 51 studies by cancer type
Site of malignancy | Histopathological type | No. of studies | Total no. of patients | Specimen state | Summative evidence |
|---|---|---|---|---|---|
Cervical | Cervical SCC | 4 | 638 | In-vivo | Stronga |
Prostate | – | 12 | 297 | Both | Strong |
Skin | Skin melanoma & NMSC | 7 | 3009 | In-vivo | Moderate |
Breast | Various carcinomas | 12 | 2460 | Both | Moderate |
Oral mucosa | SCC | 2 | 198 | In-vivo | Moderate |
Bladder | – | 3 | 123 | Both | Moderate |
Thyroid | Various carcinomas | 1 | 27 | In-vivo | Moderate |
Colorectal | Adenocarcinoma | 1 | 22 | Ex-vivo | Moderate |
Tongue | SCC | 2 | 29 | In-vivo | Weak |
Lung | Various | 2 | 138 | Both | Weak |
Hepatic | Metastases | 2 | 16 | Ex-vivo | Weak |
Oesophagus | SCC & adenocarcinoma | 1 | 23 | In-vivo | Weak |
Gastric | Adenocarcinoma | 1 | 45 | In-vivo | Weak |
Renal | Renal cell carcinoma | 1 | 10 | Ex-vivo | Weak |